Literature DB >> 1283577

Quality of life in the treatment of hypertension. The effect of calcium antagonists.

A Fletcher1, C Bulpitt.   

Abstract

The effects of calcium antagonists on psychological well-being, cognitive function, activity and physical symptoms in hypertensive patients are reviewed. Effects on these aspects of quality of life appear to differ according to whether a dihydropyridine calcium antagonist such as nifedipine is employed or verapamil, which is a phenylalkylamine derivative. Nifedipine has been associated with a self-assessment of impaired cognitive function in 2 clinical trials. Nifedipine was also associated with more symptomatic complaints than both atenolol and verapamil in different studies. The problems with nifedipine centred on oedema, flushing and palpitations. Verapamil was associated with constipation. Compared with other classes of antihypertensive drugs, the position of calcium antagonists with respect to the maintenance of patients' quality of life is presently unclear. Verapamil has been associated with improved quality of life compared with propranolol (a beta-blocker) and nifedipine. Verapamil appears to have similar effects on quality of life as atenolol and the angiotensin converting enzyme (ACE) inhibitor, captopril. The position of nifedipine remains unclear.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1283577     DOI: 10.2165/00003495-199200441-00026

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  25 in total

Review 1.  The role of calcium channel blockers in the treatment of hypertension.

Authors:  A K Halperin; L X Cubeddu
Journal:  Am Heart J       Date:  1986-02       Impact factor: 4.749

2.  Increased antidepressant use in patients prescribed beta-blockers.

Authors:  J Avorn; D E Everitt; S Weiss
Journal:  JAMA       Date:  1986-01-17       Impact factor: 56.272

3.  Hypertensive black men and women. Quality of life and effects of antihypertensive medications. Black Hypertension Quality of Life Multicenter Trial Group.

Authors:  S H Croog; B W Kong; S Levine; M R Weir; R M Baume; E Saunders
Journal:  Arch Intern Med       Date:  1990-08

4.  The effects of verapamil and propranolol on quality of life in hypertension.

Authors:  A E Fletcher; P C Chester; C M Hawkins; A N Latham; L A Pike; C J Bulpitt
Journal:  J Hum Hypertens       Date:  1989-04       Impact factor: 3.012

5.  Double-blind placebo-controlled trial of flunarizine as add-on therapy in epilepsy.

Authors:  J Overweg; C D Binnie; J W Meijer; H Meinardi; S T Nuijten; S Schmaltz; A Wauquier
Journal:  Epilepsia       Date:  1984-04       Impact factor: 5.864

6.  The effects of antihypertensive therapy on the quality of life.

Authors:  S H Croog; S Levine; M A Testa; B Brown; C J Bulpitt; C D Jenkins; G L Klerman; G H Williams
Journal:  N Engl J Med       Date:  1986-06-26       Impact factor: 91.245

7.  Disparate effects of initial antihypertensive therapy on well-being.

Authors:  H Otten; R Schmeider; H Rüddel
Journal:  J Hypertens Suppl       Date:  1987-02

8.  Impairment of memory function by antihypertensive medication.

Authors:  S Solomon; E Hotchkiss; S M Saravay; C Bayer; P Ramsey; R S Blum
Journal:  Arch Gen Psychiatry       Date:  1983-10

9.  A comparison of long acting nifedipine and enalapril in elderly hypertensives: a randomised, single-blind, cross-over study.

Authors:  N L Gilchrist; M G Nicholls; T C Ewer; J H Livesey; R Sainsbury
Journal:  J Hum Hypertens       Date:  1988-06       Impact factor: 3.012

10.  Depression associated with nifedipine-induced calcium channel blockade.

Authors:  F J Hullett; S G Potkin; A B Levy; R Ciasca
Journal:  Am J Psychiatry       Date:  1988-10       Impact factor: 18.112

View more
  1 in total

Review 1.  What is a preferred angiotensin II receptor blocker-based combination therapy for blood pressure control in hypertensive patients with diabetic and non-diabetic renal impairment?

Authors:  Samir G Mallat
Journal:  Cardiovasc Diabetol       Date:  2012-04-10       Impact factor: 9.951

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.